Innoviva, Inc. (INVA)
21.35
+0.27
(+1.28%)
USD |
NASDAQ |
Sep 02, 16:00
21.35
0.00 (0.00%)
After-Hours: 18:50
Innoviva Research and Development Expense (TTM) : 28.66M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.66M |
| March 31, 2026 | 31.45M |
| December 31, 2025 | 30.60M |
| September 30, 2025 | 29.71M |
| June 30, 2025 | 19.60M |
| March 31, 2025 | 14.17M |
| December 31, 2024 | 13.65M |
| September 30, 2024 | 12.34M |
| June 30, 2024 | 12.78M |
| March 31, 2024 | 25.21M |
| December 31, 2023 | 33.92M |
| September 30, 2023 | 41.55M |
| June 30, 2023 | 49.29M |
| March 31, 2023 | 48.18M |
| December 31, 2022 | 41.43M |
| September 30, 2022 | 31.49M |
| June 30, 2022 | 20.21M |
| March 31, 2022 | 6.365M |
| December 31, 2021 | 0.576M |
| September 30, 2021 | 0.755M |
| June 30, 2021 | 1.316M |
| March 31, 2021 | 1.837M |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 |
| Date | Value |
|---|---|
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.342M |
| June 30, 2018 | 0.653M |
| March 31, 2018 | 1.001M |
| December 31, 2017 | 1.355M |
| September 30, 2017 | 1.358M |
| June 30, 2017 | 1.333M |
| March 31, 2017 | 1.355M |
| December 31, 2016 | 1.393M |
| September 30, 2016 | 1.77M |
| June 30, 2016 | 2.031M |
| March 31, 2016 | 2.299M |
| December 31, 2015 | 2.619M |
| September 30, 2015 | 2.674M |
| June 30, 2015 | 4.036M |
| March 31, 2015 | 5.523M |
| December 31, 2014 | 48.20M |
| September 30, 2014 | 81.05M |
| June 30, 2014 | 110.74M |
| March 31, 2014 | 140.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Zevra Therapeutics, Inc. | 14.83M |
| Collegium Pharmaceutical, Inc. | -- |
| CorMedix, Inc. | 27.59M |
| ANI Pharmaceuticals, Inc. | 49.91M |
| Corcept Therapeutics, Inc. | 253.86M |